{"id":151,"date":"2019-06-24T12:06:10","date_gmt":"2019-06-24T16:06:10","guid":{"rendered":"http:\/\/blogs.duanemorris.com\/lifescienceslaw\/?p=151"},"modified":"2019-06-24T12:06:10","modified_gmt":"2019-06-24T16:06:10","slug":"fda-comments-on-the-public-hearing-on-products-containing-cannabis-and-cannabis-derived-compounds-and-extends-comment-period","status":"publish","type":"post","link":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2019\/06\/24\/fda-comments-on-the-public-hearing-on-products-containing-cannabis-and-cannabis-derived-compounds-and-extends-comment-period\/","title":{"rendered":"FDA Comments on the Public Hearing on Products Containing Cannabis and Cannabis-Derived Compounds and Extends Comment Period"},"content":{"rendered":"<p>At the U.S. Food and Drug Administration\u2019s (FDA) public hearing on May 31, 2019 (<a title=\"How Will FDA Bring Order to the Wild West of Cannabis Regulations?\" href=\"https:\/\/blogs.duanemorris.com\/cannabis\/2019\/06\/11\/how-will-fda-bring-order-to-the-wild-west-of-cannabis-regulations\/\" target=\"_blank\" rel=\"noopener noreferrer\">read more<\/a>\u00a0about the hearing), over 100 people presented to a panel of FDA stakeholders and to over 500 attendees. Last week, FDA stated in a\u00a0<a title=\"FDA is Committed to Sound, Science-based Policy on CBD\" href=\"https:\/\/www.fda.gov\/news-events\/fda-voices-perspectives-fda-leadership-and-experts\/fda-committed-sound-science-based-policy-cbd\" target=\"_blank\" rel=\"noopener noreferrer\">post<\/a>\u00a0that it recognizes the \u201csignificant public interest in these products, for therapeutic purposes and otherwise\u201d but reiterated that \u201cthere are many unanswered questions about the science, safety, and quality of many of these products.\u201d<\/p>\n<p>The good news for the industry is that FDA \u201crecognize[s] the need to be clear and open about where things stand, and about the efficient and science-based way in which we are moving forward,\u201d including \u201cbeing transparent and up-front\u201d as they continue to collect data and information on CBD. FDA is taking an \u201cAgency-wide, integrated, and collaborative approach\u201d to regulating products made from CBD and is exploring potential pathways to market for CBD products. However, FDA still grapples with how to balance the desire for widespread availability of CBD products with the desire to preserve incentives for research and drug development of CBD products.<\/p>\n<p><a href=\"https:\/\/www.duanemorris.com\/alerts\/fda_public_hearing_products_containing_cannabis_derived_compounds_extends_0619.html\">View the full <em>Alert <\/em>on the Duane Morris LLP website<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>At the U.S. Food and Drug Administration\u2019s (FDA) public hearing on May 31, 2019 (read more\u00a0about the hearing), over 100 people presented to a panel of FDA stakeholders and to over 500 attendees. Last week, FDA stated in a\u00a0post\u00a0that it recognizes the \u201csignificant public interest in these products, for therapeutic purposes and otherwise\u201d but reiterated &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2019\/06\/24\/fda-comments-on-the-public-hearing-on-products-containing-cannabis-and-cannabis-derived-compounds-and-extends-comment-period\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;FDA Comments on the Public Hearing on Products Containing Cannabis and Cannabis-Derived Compounds and Extends Comment Period&#8221;<\/span><\/a><\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[374,375,360,29,376,50,119],"ppma_author":[521],"class_list":["post-151","post","type-post","status-publish","format-standard","hentry","category-uncategorized","tag-cannabis","tag-cannabodiol","tag-cbd","tag-fda","tag-fda-cannabis","tag-pharma","tag-rick-ball"],"authors":[{"term_id":521,"user_id":6,"is_guest":0,"slug":"duanemorris3","display_name":"Duane Morris","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/843ff6e7a8fe5fc92109b47a45f34b6cf0ea499e6e788db23456c838b0ae6747?s=96&d=blank&r=g","0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/151","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/comments?post=151"}],"version-history":[{"count":0,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/151\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/media?parent=151"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/categories?post=151"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/tags?post=151"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/ppma_author?post=151"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}